The first recipient of a genetically modified pig heart passes the one-year survival milestone with stable cardiac function and no organ rejection.
The University of Maryland Medical Center has announced that the first recipient of a genetically modified pig heart has surpassed the one-year survival milestone, marking an unprecedented achievement in the field of xenotransplantation. The patient, a 58-year-old man who had been ineligible for a human heart transplant, continues to show stable cardiac function and no signs of organ rejection.
The pig heart was modified using ten genetic edits designed to prevent immune rejection and remove pig viruses that could potentially infect human cells. The surgical team, led by Dr. Bartley Griffith, performed the groundbreaking procedure in January 2024 after years of preclinical research in non-human primates.
Immunological monitoring has revealed a remarkably stable profile. The patient's immune system initially mounted a mild response to the pig organ, but a carefully calibrated immunosuppression regimen successfully prevented acute rejection episodes. Endomyocardial biopsies performed monthly show healthy tissue with no signs of the chronic rejection that plagued earlier xenotransplantation attempts.
The success has electrified the transplant community. Over 100,000 people in the United States alone are currently on organ transplant waiting lists, and approximately 17 people die each day while waiting for a donor organ. Pig-to-human transplantation could effectively eliminate the organ shortage if the technology can be scaled safely.
Several additional patients have since undergone pig organ transplants, including kidney transplants at NYU Langone Health and Massachusetts General Hospital. While outcomes have been varied, the overall trajectory is encouraging, with survival times steadily increasing as surgical teams and immunologists refine their approaches.
The FDA is working closely with xenotransplantation research centers to develop a regulatory framework for clinical trials. A formal Phase I trial protocol is expected to be submitted within the next six months, potentially opening the door to broader access for patients with end-stage organ failure.
Ethical discussions continue regarding the welfare of genetically modified animals bred for organ donation, the equitable allocation of xenotransplant organs, and the long-term monitoring requirements for recipients. These conversations involve bioethicists, patient advocacy groups, and religious leaders to ensure that the technology advances in a manner consistent with societal values.